Shares of Cadila Healthcare gained more than 2% on the BSE after the USFDA completed its inspection at the company’s Ahmedabad plant.
The company informed that the USFDA inspected the manufacturing facility of Alidac Pharmaceuticals, the company’s wholly-owned subsidiary, located at SEZ, Ahmedabad from January 27, 2020, to February 4, 2020. At the end of the inspection, no observation (483) is issued, the company said in the press note on Tuesday.
The site manufactures oncology injectable for the regulated markets, it added.
The company will declare its third-quarter earnings today.
Cadila Healthcare Ltd is currently trading at Rs270.20, up by Rs6.15 or 2.33% from its previous closing of Rs264.05 on the BSE.
The scrip opened at Rs266.70 and has touched a high and low of Rs272.55 and Rs266.70 respectively.
For Quick Trial – 8871888787
or mail us here - support@researchicon.com
or visit - http://www.researchicon.com/free-trial
إرسال تعليق